Dr Robert Holloway explains what second-line treatment regimen he would have chosen for the patient with metastatic endometrial cancer in the presented case.
Case History
June 2021
A 71-year-old postmenopausal woman presented with intermittent uterine bleeding, increased urinary frequency, and cramping over the past 6 months.
July 2021:
May 2022 (6 months post–chemotherapy completion):
Powell Reviews Updated IO/TKI Data and AE Management in Endometrial Cancer
April 18th 2024During a Case-Based Roundtable® event, Matthew A. Powell, MD, discussed the case of a patient with advanced endometrial cancer treated with lenvatinib plus pembrolizumab who experienced grade 2 treatment-related hypertension.
Read More
Roundtable Roundup: Surveying Oncologists on Endometrial Cancer Treatment
March 27th 2024Bhavana Pothuri, MD, and Krishnansu S. Tewari, MD, discussed the treatment options of a patient with advanced endometrial cancer and participants chose an immune checkpoint inhibitor to use for therapy.
Read More